Seeking people aged 18 and older whose COVID-19 symptoms have returned ( COVID-19 rebound) after having completed a 5-day course of Paxlovid antiviral medication treatment for a study of an investigational drug for rebound COVID-19.
Participants in this study will receive either the investigational drug or a placebo (looks like the drug, but contains no medication). There will be up to 10 study visits over 24 weeks.
What we're hoping for
We are studying whether the investigational drug is safe and effective compared to placebo for people whose COVID-19 symptoms return (rebound COVID-19) following completion of Paxlovid antiviral therapy for an initial COVID-19 infection.
ClinicalTrials.gov Identifier: NCT05567952